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Raman spectroscopy provides a unique biochemical fingerprint capable of identifying and characterizing the structure ofmolecules,
cells, and tissues. In cervical cancer, it is acknowledged as a promising biochemical tool due to its ability to detect premalignancy
and early malignancy stages. This review summarizes the key research in the area and the evidence compiled is very encouraging
for ongoing and further research. In addition to the diagnostic potential, promising results for HPV detection and monitoring
treatment response suggest more than just a diagnosis prospective. A greater body of evidence is however necessary before Raman
spectroscopy is fully validated for clinical use and larger comprehensive studies are required to fully establish the role of Raman
spectroscopy in the molecular diagnostics of cervical cancer.
1. Raman Spectroscopy—What Is It and How
Does It Work?
The physical phenomenon of Raman scattering, also known
as the Raman effect, has been extensively studied since it was
first discovered in 1928 by the Indian physicist C. V. Raman.
It works on the principle that a small fraction (approximately
1 in 10million) of the radiation scattered by certainmolecules
differs from that of the incident beam, and that the shift
in wavelength depends upon the chemical structure of the
molecules responsible for the scattering [1]. Raman spectra
are acquired by irradiating a sample with a powerful laser
source of usually visible or near-infrared monochromatic
radiation and measuring the scattered radiation with a suit-
able spectrometer [1, 2]. Figure 1 shows the process involved
in collection of Raman spectra.
Knowing the frequency of the incident light and measur-
ing the frequency of the Raman scattered light, it is possible
to calculate the vibrational energy difference. This energy
is known as the Raman shift and is usually expressed in
wavenumbers (cm−1) in a plot known as the Raman spec-
trum. Raman spectral features can be used as identification
markers of particular substances because complex molecules
have several specific vibrational energy modes allowing the
Raman spectrum of each substance to be highly specific
and distinctive [3]. Figure 2 shows an example of a Raman
spectrum recorded from a cervical cancer cell line, CaSki.
The full spectral range is shown from 400 to 3500 cm−1,
including the fingerprint region, 400 to 1800 cm−1, and the
high wavenumber (HW) region, 2800 to 3500 cm−1. Figure 3
shows the fingerprint region in more detail with the major
assignments related to glycogen, proteins, lipids, and nucleic
acids highlighted.
Raman spectroscopy has been applied in numerous sci-
entific fields, from chemistry and biochemistry to arts and
archaeology, as a powerful spectroscopic technique which
allows a spectral fingerprint capable of identifying the struc-
ture and function of molecules, cells, tissues, or materials
[4, 5]. In particular, its application to medical diagnostics has
been of increasing interest in the past few decades [6].
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Figure 1: Schematic showing the process involved in Raman
spectra collection. When the sample is illuminated by an incident
monochromatic light, the majority of the scattered light is of the
same wavelength—elastically scattered (green arrow). A notch filter
is therefore used to block the elastically scattered light which would
otherwise overwhelm the weak signal of the Raman or inelastically
scattered light (orange arrow). The Raman scattered light may be
dispersed according to wavelength through a grating and detected
by a CCD (charge-coupled device) detector. A Raman spectrum is
finally shown upon software analysis.
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Figure 2: Raman spectrum of cervical cancer CaSki cell line. The
variation of Raman shift wavelength is expressed in wavenumbers
(cm−1) and can be observed along the 𝑋-axis whilst the intensity
is represented along the 𝑌-axis. The fingerprint and the high
wavenumber (HW) regions of the spectrum are indicated by the
arrows.
Raman spectroscopy has been reported for the detection
of different types of pathologies, including cancer [4, 6–11].
A large number of studies concerning the investigation of
cervical cancer with this particular vibrational spectroscopic
technique have demonstrated its usefulness in understanding
the disease progression at the molecular level. This review
aims to compile the most significant achievements in this
emerging research area. Methodologically, PubMed, Web of
Science, and publicly available websites were searched for
original data and literature in English using the following key-
word combination: cervical cancer and Raman spectroscopy.
2. Cervical Cancer
Cervical cancer refers to any malignant neoplasm arising
from the uteri cervix. As the fourth most common cancer
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Figure 3: Fingerprint region of the Raman spectrum of cervical
cancer CaSki cell line. The major assignments related to glycogen,
proteins, lipids, and nucleic acids are highlighted.
in women worldwide and the fourth leading cause of female
cancer deaths, cervical cancer is a key research area [12]. Its
most common onset site is the cellular junction or transfor-
mation zone, where the stratified squamous epithelium of the
ectocervixmeets the columnarmucus-secreting epitheliumof
the endocervix.Themost frequent types of cervical cancer are
thus squamous cell carcinoma (SCC) and adenocarcinoma
(ADC) [13, 14].
Persistent Human Papilloma Virus (HPV) infection is
accepted as the leading aetiological agent for cervical cancer
[15]. HPV is a circular double-strand DNA virus of almost
8000 bp belonging to the Papillomaviridae family. Frommore
than 150 different genotypes, only 40 are reported to infect
the anogenital tract, typically classified as high- or low-risk
according to their ability to cause a recurrent infection [15,
16]. After HPV infection, dysplasia usually develops in the
transformation zone. Low grade dysplasia can spontaneously
regress without leading to cervical cancer [13, 17]. However
some lesions progress to moderate and subsequently severe
dysplasia, finally progressing to invasive cancer. For this
reason, cervical cancer is postulated as a progressive disease
[13, 17].
The implementation of coordinated and organized cytol-
ogy screening programmes in developed countries has
resulted in a marked decrease of the disease over the past
decades; however cervical cancer is still a major problem in
developing countries where approximately 80% of the cases
occur [18]. The existing screening programmes are based
on the microscopic evaluation of liquid based cytology and
despite a high specificity of 95 to 98%, sensitivity varies from
74 to 96% [19, 20]. For this reason, other methods such as
automated cytology and HPV testing have been studied in an
attempt to reduce false negative rates.
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An abnormal Pap smear is usually followed by colposco-
py, biopsy, and histological confirmation of the diagnosis.
Despite its slowness the major concerns about this procedure
are the subjectivity of the grading characteristics and the
fact that premalignancy or early malignancy stages could be
missed due to their low morphologic perceptibility. Along-
side other spectroscopy techniques such as FTIR (Fourier
Transform Infrared) [21–23] and fluorescence spectroscopy
[24–26], Raman spectroscopy has, in recent years, been
acknowledged as a promising biomedical tool.
3. Raman Spectroscopy for Cervical Cancer
Table 1 compiles all the Raman spectroscopy studies concern-
ing cervical cancer reported in the literature until September
2014 and discussed in this review. For clarity purposes it
is important to explain a few terms that will be recurrent
throughout the review. In vivo measurements relate to those
acquired directly from the cervix of patients, ex vivo refers
to the measurements acquired from the surface of biopsies
and other surgical material extracted from the patients’
cervix, and in vitro refers to spectra obtained from cell
lines. Formalin fixed paraffin preserved (FFPP) histological
sections and cytology samples are referred to separately.
3.1. In Vivo Spectra Recorded from the Patient. Mahadevan-
Jansen et al. in 1998 were the first to show the potential of
Near Infrared (NIR) Raman spectroscopy to detect cervical
precancers amongst other pathologies. They developed a
compact fibre-optic probe which they used to record ex vivo
and in vivo spectra [27, 28].
The overall ex vivo conclusions stated that, in the Raman
spectrum of squamous intraepithelial lesions, peaks attribut-
ed to collagen (1656, 1070 cm−1) consistently decreased in
intensity while peaks assigned to phospholipids, DNA, and
glucose 1-phosphate (1454, 1330, and 978 cm−1) increased
in intensity. These findings were attributed with tumour
progression, as the number of cells in the epithelium increases
with lesion development. Furthermore, multivariate statis-
tical analysis allowed the differentiation of precancers from
all other tissues with sensitivity and specificity rates of 82%
and 92%, respectively [28]. Their exploratory in vivo results
showed broadly similar Raman spectra at the fingerprint
region [27].Themain differences were (1) a band at 936 cm−1
only observed in vivo, (2) a peak at 978 cm−1 that was not
consistently observed in ex vivo spectra, and (3) an amide
band at 1252 cm−1 that was more prominent in the in vivo
spectra.The authors highlighted the need to increase patient
numbers so the in vivo technology could be clinically relevant
[28].
Advances in fiber-optic technology led Utzinger et al.
to further assess the viability of Raman spectroscopy to
detect and classify cervical precancer lesions [29]. In a
small clinical trial it was concluded that Raman spectra
acquired from in vivo sampling were comparable with
histopathology reports. The results showed increased Raman
intensity of phospholipids and DNA assignments, ∼1330,
1454, and 1650 cm−1, respectively, as the lesions progressed to
high-grade dysplasia [29]. Despite these encouraging results,
the authors noted the heterogeneity of the tissue and thus the
possible contribution of normal epithelial cells to the spectral
data. It was also suggested that further technological advances
were once again needed to assess performance in large scale
clinical trials [29].
The same group have investigated the influence of hor-
monal changes, particularly menstrual cycle andmenopausal
state, and by introducing these into the in vivo diagnosis
algorithm, Kanter et al. improved the overall accuracy of
Raman spectroscopy to 94% [30] reaching 97% for low-grade
dysplasia detection [31]. Postmenopausal, perimenopausal,
and premenopausal normal cervix before and after ovula-
tion showed subtle but consistent differences at 1250 cm−1
and 1300–1320 cm−1, assigned to collagen and other cellular
features like lipids, Amide III, and nucleotides [31]. Similarly,
previous disease history and the proximity to malignant
lesions were also shown to influence Raman spectral profiles.
The principal qualitative differences between “true” normal
and “previous disease” normal spectra were found in the
1200–1400 cm−1 range where assignments to proteins and
collagen type Iwere higher in “true” normal spectrawhilst the
DNA and glycogen assignments (∼1330 cm−1) were higher
in “previous disease” normal Raman spectra [32]. The same
range was also found to comprise the most significant differ-
ences between Raman spectra of “true” normal, “adjacent to
disease” normal, and low- and high-grade dysplasia. Collagen
assignment was again higher in both “true” and “adjacent to
disease” normal whereas DNA was higher in low and high-
grade dysplasia [32].
In an attempt to further establish the greatest sources of
intraclass variation among normal Raman spectra, Vargis et
al. investigated race and ethnicity, body mass index (BMI),
parity, and socioeconomic status in their in vivo study. The
results showed that only BMI and parity were significant
sources of variation within normal spectra. Their influence
on dysplasia and disease remains to be assessed [33].
3.2. Ex Vivo Spectra Recorded from Excised Patient Tissue.
Krishna et al. reported Raman spectral differences between
normal and malignant biopsy samples. Amides I and III and
structural proteins such as collagen seemed to be character-
istic of normal tissue whilst DNA, lipids, and noncollagenous
proteins dominated the abnormal spectral features [34].
Keller et al. showed that Raman spectral profiles from the
stroma below epithelium with HPV associated histological
changes had differences in DNA (1316 and 1334 cm−1) and
glycogen (1048, 1083, 1256, and 1333 cm−1) assignments [35].
Further differences at 1260 and 1304 cm−1 Amide III band
were proposed to be related with the angiogenesis process
or to the fact that disease may have extended without visible
histologically effects [35]. While increased DNA levels and
decreased glycogen levels as dysplasia progresses had been
described before, this was the first report of alterations of
the histologically normal stroma below diseased epithelium.
Further study is therefore warranted as disease classification
depends on stromal invasion.
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The role of cervicitis in Raman spectroscopy diagnosis of
low-grade dysplasia was investigated by da Silva Martinho et
al. Despite an overall sensitivity and specificity of 93% and
85%, the results showed that spectral changes observed at 857,
925, ∼1247, 1370, and 1525 cm−1 vibrational bands resulted in
the cervicitis group falling mid-way between the normal and
low-grade dysplasia groups. The data showed that a severe
inflammatory condition such as cervicitis makes the identifi-
cation and correct diagnosis of early malignancy stages such
as low-grade dysplasia difficult and must therefore be taken
into account when developing data analysis algorithms [36].
Finally NIR micro-Raman spectroscopy study by
Kamemoto et al. showed that Raman spectra from collagen
bands at the low frequency 775–975 cm−1 region distinguish
normal from cervical cancer cells, and that this is concordant
with the analysis of C–H stretching in high wavenumber
region (2800–3700 cm−1) [37].
3.3. FFPP Sections Spectra Recorded fromHistological Sections.
Archival FFPP material is extremely valuable as it allows
retrospective studies to be undertaken after diagnosis and
outcome is known. Raman spectroscopy studies have been
undertaken on histological FFPP sections further confirming
Raman spectroscopy as a powerful informative tool in cervi-
cal cancer research.
Krishna et al. studied formalin fixed cervical tissues by
both Raman and FTIR spectroscopy, reporting the discrim-
ination of malignant tissues through both techniques. In
Raman spectra, differences in protein, lipids, and nucleic acid
peaks were observed along with stronger Amide III assign-
ments which is supportive of disordered, helical secondary
structure of protein components in malignant conditions
[38].
Further confirmation of the potential of Raman spec-
troscopy for cervical cancer was reported by Lyng et al.
who demonstrated the viability of using FFPP samples and
investigated the underlying biochemical changes associated
with cervical precancer and cancer [39]. Results showed a
reduction in glycogen bands at 482, 849, and 938 cm−1 and
an increase in nucleic acid bands at 724, 779, 829, 852, 1002,
1098, 1240, and 1578 cm−1 in cervical precancer and cancer.
An increase intensity of Amide I was also reported [39].
3.4. In Vitro Spectra Recorded from Cell Lines. Yazdi et al.
described the use of UV resonance Raman spectroscopy
at 257 nm to distinguish between normal and malignant
breast [MCF-10A, MCF-7 McGuire, and MDA-MB435] and
cervical [CrEc-Ec 4665 (primary culture from normal cervix
epithelium), SiHa, and HeLa] cultured cells. They reported
an increase in DNA/protein ratio and a change in the purine
scattering in malignant cells, suggesting the application of
resonance Raman spectroscopy in cytology screening by
monitoring DNA and RNA differences between normal and
abnormal cells [40].
Despite being the main aetiological factor in cervical
cancer, HPV was only investigated by Raman spectroscopy
towards the end of the last decade with a cell culture
study by Jess et al. [41]. Raman microspectroscopy was
used to discriminate PHK (primary human keratinocytes),
PHK E7 and CaSki cells, where PHK E7 cells express the
E7 gene of HPV16 and CaSki expresses HPV16. The mean
Raman spectra showed variations at DNA and protein level,
consistent with HPV gene expression and malignancy in
both live and fixed cells. Together with principal component
analysis (PCA) results, Raman spectroscopy was shown to be
a valuable tool in identifying and characterizing the different
stages of HPV-associated malignancies [41].
Ostrowska et al. applied both FTIR and Raman spec-
troscopy to the study of cervical cancer cell lines. Their data
suggest that HPVnegative (C33a) and lowHPV copy number
(SiHawith 1-2 copies) cell lines are biochemically very similar
but significantly different frommid (HeLa) and high (CaSki)
HPV copy number cell lines. The main variations were
observed for protein, nucleic acid, and lipid levels and were
confirmed by both mean spectra and PCA analysis [42].
Discrimination of the cell lines based on HPV integration
shows the potential of Raman spectroscopy to identify HPV
induced biochemical changes [42].
Worthy of highlight is also a comparative study by Kim
et al. [43] of the distribution of intracellular components in
cells expressing HPV16 E6 oncoprotein. The key finding of
this Raman mapping study is that E6 oncoprotein expression
induces major phenotypic changes in the cells which are also
targeted by an HIV antiviral drug—Indinavir [43].
Vargis et al. [44] also showed Raman microspectroscopy
to successfully detect HPV and differentiate specific virus
strains, in a complementary cell line and in vivo study with
cellular pellets from cytology samples. Normal HPV negative
cell line NHEK was used alongside three cervical carcinoma
cell lines: HPV positive (HeLa and SiHa) and HPV negative
C33a. Specificity values of 89–97% for cell lines and 98.5%
for cytology samples are extremely encouraging and confirm
the enormous potential of Raman spectroscopy to provide an
accurate differential diagnosis [44].
3.5. Cytology Spectra Recorded from Exfoliated Cells. Rubina
et al. used Raman spectroscopy to distinguish between 49
cervical cancer and 45 negative control cytology samples.
Cellular pellets were generated from ThinPrep material and
subjected to Raman analysis. Amide I (1660 cm−1), 𝜕CH
2
(1450 cm−1), and phenylalanine (1002 cm−1) were the main
features dominating the control Raman spectra whereas the
spectra of cervical cancer samples were dominated by blood
features such as fibrin (1570 cm−1) and heme (1620 cm−1).
PCA-LDA (linear discriminant analysis) showed a classifi-
cation efficiency of ∼90% but the loadings were suggestive
of blood as the major discriminative factor between the two
groups. As bleeding is a common occurrence in cervical
infections, uterine cancer, and menstrual cycle, 57 samples
(28 controls and 29 cancers) were further treated with red
blood cell lysis buffer prior toRaman acquisition.The absence
of heme and fibrin bands confirmed the effective removal of
blood from the samples and an increase in protein content
(at 1006, 1450, and 1660 cm−1) and change in their secondary
structure due to positive Amide III bands was observed.
In this case the PCA-LDA analysis showed a classification
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efficiency of ∼80%. Sample heterogeneity and the fact that
the distribution of the abnormal cells in the cervical cancer
specimens can vary from 1-2% to 20–40% were suggested as
the major causes of misclassification. The authors suggested
further studies on pure cancerous and precancerous speci-
mens as ameans to build standard and validationmodels that
could then be applied to blinded specimens [45].
3.6. Treatment Response. In their dual Raman and FTIR
study, already mentioned in the FFPP section, Krishna et
al. also presented data concerning Raman spectra after
radiotherapy cycles, showing small changes, especially in
antioxidant levels [38]. In a further ex vivo pilot study to
detect radiotherapy response [46], tissues were collected after
a second fraction of radiotherapy and classified based on
clinical evaluation into complete, partial, and no response.
Raman spectra were acquired and PCA provided a clear sep-
aration between responding and nonresponding samples as
well as between complete and partial radiotherapy response.
In a more recent ex vivo study, Rubina et al. explored the
feasibility of fibre-optic-based Raman spectroscopy in pre-
dicting tumour response to concurrent chemoradiotherapy.
Their PCA classification pattern also showed encouraging
results despite the need of a greater body of evidence [47].
A study by Duraipandian et al. used HW Raman spec-
troscopy to noninvasively assess, in vivo, the effect of Vagifem
(oestrogen therapy) treatment in women [48]. A bimolecular
Raman spectroscopy model could not only successfully
identify hormone/menopausal related changes in cervical
epithelium, but also assess the effect of Vagifem treatment
during colposcopic inspections as the protein and lipid
Raman signals increase after treatment and start to resemble
premenopausal values [48].
3.7. Improving Data Analysis and Recording. Improving over-
all sensitivity and specificity of Raman spectroscopy for in
vivo diagnosis of cervical cancer has also led researchers to
address better algorithms andmethods for statistical analysis.
A study by Kanter et al. explored binary and multiclass
discrimination algorithms to analyse Raman spectroscopy
data: maximum representation and discrimination feature
(MRDF) and sparse multinomial logistic regression (SMLR).
Although both algorithms provided an improvement over
the current method of diagnosis, colposcopy-guided biopsy
(with sensitivity of 87% and specificity of 72%), the use of
a multiclass algorithm improved the overall Raman spec-
troscopy sensitivity from 92% to 98% and the specificity from
81% to 96% [49].
Similarly, Duraipandian et al. investigated the application
of genetic algorithm-partial least squares-discriminant anal-
ysis (GA-PLS-DA) with double cross-validation (dCV). By
employing a GA-PLS-DA algorithm which used significant
Raman bands selected from 925–935, 979–999, 1080–1090,
1240–1460, 1320–1340, 1400–1420, and 1625–1645 cm−1, a
72.5% specificity and 89.2% sensitivity for precancer detec-
tion were achieved and could therefore be further investi-
gated as a feasible alternative to current PCA methods [50].
Still in the in vivo context, modifications in the recording
process have also been considered and reported in the
literature. HW Raman spectroscopy, 2800–3700 cm−1, was
successfully described by Mo et al. with 93.5% and 97.8%
diagnostic sensitivity and specificity, respectively [51]. The
results showed that the intensity of the Raman signal within
the 2800–3035 cm−1 range, which comprises proteins and
lipids, fromdysplastic tissue, was significantly lower than that
observed for normal tissue. An increase in the vibrational sig-
nal of water from the dysplastic tissue was also observed and
in line with that reported by FTIR spectroscopy [10, 11]. The
authors further supported these observations with literature
concerning the increase of aquaporins at the dysplastic cell
membrane and the fact that higher DNA levels or hydration
of DNA due to the unfolding step in cell division could also
account for this observation [51].
Simultaneous fingerprint and HW Raman spectroscopy
have also been described by Duraipandian et al. who showed
their complementary potential and ability to improve early
disease detection.The sensitivity and specificity values of 85%
and 81.7%, respectively, for integrated fingerprint and HW
Raman spectroscopy were shown to be higher than those of
fingerprint or HW Raman spectroscopy alone [52].
3.8. Future Perspectives. An exploratory work on surface-
enhanced Raman spectroscopy (SERS) for cervical can-
cer diagnosis through blood plasma analysis was recently
reported by Feng et al. Comparing blood plasma samples
from clinically and histopathologically confirmed healthy
volunteers and cervical cancer patients, results showed that
PCA-LDA algorithms yielded better sensitivity (96.7%) and
specificity (92%) than empirical algorithms based only on
the integration area of SERS spectral bands of 1310–1430 and
1560–1700 cm−1 [53].
Along the same lines, Gonza´lez-Sol´ıs et al. published a
study on cervical cancer detection based on Raman spec-
troscopy of serum samples. The study reported higher levels
of carotenoids and protein components in control samples
whereas assignments to glutathione and tryptophan were
more intense in the spectra of abnormal samples. Despite a
small number of patient samples (3 CIN I and 19 SCC), PCA
analysis yielded a sensitivity of 100% and a specificity of 97.1%
[54].
4. Summary
All pathologies are marked by fundamental biochemical
changes at the molecular, cellular, and tissue level. The
identification and further understanding of these changes
would allow improved diagnosis and treatments, as well as
overall management and disease survival. The potential of
Raman spectroscopy in molecular diagnostics relies on its
ability to determine and characterize the unique fingerprint
of a sample at the biochemical level.
The high incidence rate of cervical cancer as well as its
progressiveness has led researchers to continually examine
and pursue better diagnosis, prognosis, and treatment tech-
niques to decrease mortality rates and comorbidity from the
disease. As highlighted, not only does Raman spectroscopy
have the potential to identify cancerous and precancerous
tissue, it also has the ability to probe deeper into the
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disease fingerprint to elucidate its underlying mechanisms.
By implementing variations of the technique to study a wide
range of samples such as commercially available cell lines,
FFPP sections, and in vivo and ex vivo tissue, the potential of
Raman spectroscopy as a viable option for a future diagnostic
technology of cervical cancer and other disease states has
been shown. In cervical cancer, a number of different factors
including HPV infection, hormonal imbalances, and inflam-
matory infection have already been reported to influence
Raman spectra. Whilst these could be seen as limitations,
they actually prove the sensitivity of the technique and
support additional evidence generated by other approaches
such as proteomics and virology.
However, lack of information regarding which data was
considered for the sensitivity and specificity values reported,
as well as the lack of positive and negative predictive values,
calls for the standardization in the reporting of these impor-
tant performance measurements. Likewise, sample handling
and processing ought to be reported as it can influence
Raman spectroscopy profiles. Finally, whilst acknowledging
the exploratory nature of most studies and the difficulty
in obtaining patient samples, a frank criticism is the small
sample size of most reported studies. Although spectroscop-
ically significant due to the high number of spectroscopic
measurements, more samples are required to assess the
biological and pathological relevance and reproducibility.
A far greater body of evidence is still required before
this technology can make head way in a clinical setting.
For instance, the engagement of the clinical community in
supporting more comprehensive studies both in vivo and
ex vivo, cognisant of all variables and considering a wide
range of controls, gathered from a representative spectrum
of the population would be vital to take the technique a
step closer to cervical cancer diagnosis. If such studies could
be undertaken and the reliability of the technique proven,
Raman spectroscopy could have a real future in clinical
diagnostics of cervical cancer and similar pathologies.
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